Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
|Articles|May 11, 2012
Stuart Butler, PhD, Identifies Ways to Approach Cost
Dr. Butler answers why he is not confident that costs will ever be controlled.
Advertisement
Stuart Butler, PhD, Distinguished Fellow and Director, Center for Policy Innovation, The Heritage Foundation, states that the cost curve will never go down on the track we are currently on. Dr. Butler addresses the need for new approaches to bending the curve.
Advertisement
Related to this article
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
PBM practices and split benefit coverage for oral vs IV chemotherapy drive high costs; a bill would close the gap for self-funded plans.
Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including for patients with non–small cell lung cancer.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
Twice-Yearly CD19 Therapy Targets MG Root Cause: Richard Nowak, MD, MS
3
GLP-1 Receptor Agonists Cut Ascites, Mortality in MASH
4
Hepatitis A Vaccine Prevents 96% of Infections Given Before Exposure
5